The Oncomine™ Immune Response Research Assay is a targeted gene expression assay designed for the Ion™ next-generation sequencing (NGS) platform. This pan-cancer gene expression assay is designed to interrogate the tumor microenvironment to enable mechanistic studies and identification of predictive biomarkers for immunotherapy in retrospective or prospective clinical trial research cohorts. The assay is optimized to measure the expression of genes involved in tumor-immune interactions, including the low-expressing genes involved in inflammatory signaling.